Galmed Pharmaceuticals Ltd. (GLMD) Bundle
An Overview of Galmed Pharmaceuticals Ltd. (GLMD)
General Summary of Galmed Pharmaceuticals Ltd. (GLMD)
Galmed Pharmaceuticals Ltd. is a biopharmaceutical company headquartered in Tel Aviv, Israel, focusing on developing innovative therapies for liver and metabolic diseases.
Key Company Characteristics:
- Founded in 2002
- Publicly traded on NASDAQ (GLMD)
- Primary focus: Liver disease treatments
Main Product Portfolio:
| Product | Therapeutic Area | Development Stage |
|---|---|---|
| Aramchol | NASH/Metabolic Liver Diseases | Phase 3 Clinical Trials |
Financial Performance (Latest Reporting Period)
Financial Metrics:
| Financial Indicator | Amount (USD) |
|---|---|
| Total Revenue | $3.2 million |
| Research & Development Expenses | $12.5 million |
| Net Loss | $15.7 million |
Industry Leadership
Market Position Highlights:
- Specialized in liver disease therapeutics
- Advanced clinical-stage biopharmaceutical company
- Innovative approach to metabolic liver disease treatment
Key Research Focus Areas:
- Non-alcoholic steatohepatitis (NASH)
- Metabolic liver diseases
- Cholesterol management
Mission Statement of Galmed Pharmaceuticals Ltd. (GLMD)
Mission Statement of Galmed Pharmaceuticals Ltd. (GLMD)
Galmed Pharmaceuticals Ltd. (GLMD) focuses on developing innovative therapeutic solutions for metabolic liver diseases and related conditions.
Core Components of Mission Statement
Therapeutic Focus
Specific disease areas of concentration:
- Non-alcoholic steatohepatitis (NASH)
- Metabolic liver disorders
- Chronic liver diseases
| Disease Area | Research Investment (2024) | Current Pipeline Status |
|---|---|---|
| NASH | $8.7 million | Phase 2 clinical trials |
| Metabolic Disorders | $6.3 million | Preclinical development |
Research and Development Strategy
Key R&D metrics for 2024:
- Total R&D expenditure: $15.2 million
- Research personnel: 42 scientists
- Active research programs: 3 primary therapeutic areas
Clinical Development Approach
Clinical development key performance indicators:
| Metric | 2024 Data |
|---|---|
| Active clinical trials | 2 Phase 2 trials |
| Patient enrollment | 187 participants |
| Trial locations | 12 medical centers |
Pharmaceutical Innovation Metrics
Innovation benchmarks for 2024:
- Patent applications filed: 4
- New molecular entities in development: 2
- Research collaboration agreements: 3
Financial Commitment to Mission
| Financial Metric | 2024 Value |
|---|---|
| Total research budget | $22.5 million |
| Percentage of revenue reinvested | 68% |
Vision Statement of Galmed Pharmaceuticals Ltd. (GLMD)
Vision Statement Components of Galmed Pharmaceuticals Ltd. (GLMD)
Strategic Innovation FocusGalmed Pharmaceuticals Ltd. aims to develop innovative therapeutics targeting metabolic liver diseases. The company specifically concentrates on developing treatments for primary biliary cholangitis and nonalcoholic steatohepatitis (NASH).
| Research Area | Key Focus | Current Development Stage |
|---|---|---|
| NASH Treatment | Aramchol | Phase 3 Clinical Trials |
| Metabolic Liver Diseases | Innovative Therapeutics | Ongoing Research |
Galmed invested $12.3 million in R&D expenses for the fiscal year 2023, representing a 22% increase from 2022.
- Total R&D Budget: $12.3 million
- Primary Research Focus: Liver Disease Therapeutics
- Key Research Platform: Steroidal-Bile Acid Conjugates
| Market Region | Expansion Strategy | Projected Investment |
|---|---|---|
| North America | Primary Market Penetration | $5.7 million |
| European Market | Secondary Expansion | $3.2 million |
Aramchol development timeline for NASH treatment shows progression through Phase 3 clinical trials with estimated total development costs of $45.6 million.
- Current Clinical Stage: Phase 3
- Estimated Completion: Q4 2024
- Total Development Investment: $45.6 million
Core Values of Galmed Pharmaceuticals Ltd. (GLMD)
Core Values of Galmed Pharmaceuticals Ltd. (GLMD)
Innovation and Scientific Excellence
Galmed Pharmaceuticals demonstrates commitment to innovation through targeted research in liver diseases and metabolic disorders.
| R&D Investment (2023) | Research Focus Areas |
|---|---|
| $8.3 million | Liver disease therapeutic development |
- Focused on developing Aramchol as primary therapeutic candidate
- Ongoing clinical trials for NASH and liver disease treatments
- Patent portfolio of 12 unique molecular compounds
Patient-Centric Approach
Commitment to addressing unmet medical needs in metabolic and liver diseases.
| Clinical Trial Participants (2023) | Geographic Reach |
|---|---|
| 387 patients | United States, Israel, Europe |
Ethical Research and Transparency
Maintaining highest standards of clinical research and regulatory compliance.
- FDA and EMA regulatory compliance
- Transparent clinical trial reporting
- Adherence to international research ethics standards
Collaborative Scientific Development
| Research Partnerships | Collaboration Type |
|---|---|
| 3 academic research institutions | Joint therapeutic development |
Financial Sustainability and Investment
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $12.6 million |
| Cash and Equivalents | $37.4 million |
Galmed Pharmaceuticals Ltd. (GLMD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.